Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.

ABSTRACT:

Background

Treatment with sacubitril-valsartan reduces mortality and heart failure (HF) events in HF with reduced ejection fraction and may reduce HF hospitalization in women with HF with preserved ejection fraction.

Methods

EVALUATE-HF randomized 464 participants (109 women) with HF with reduced ejection fraction to sacubitril-valsartan or enalapril for 12 weeks. Documented left ventricular ejection fraction (LVEF) ≤0.40 within the prior 12 months was required, although core laboratory LVEF>0.40 was permitted. Assessments of aortic stiffness (pulse pressure and characteristic impedance, Z_c) were performed at baseline and at trough and 4 hours postdose at weeks 4 and 12.

Results

In models of change from baseline adjusted for baseline value, treatment with s

SUBMITTER: Mitchell GF 

PROVIDER: S-EPMC12611548 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature